Adalimumab Anti-Drug Antibody

Laboratory assay overview

Adalimumab is a therapeutic monoclonal antibody with the ability to bind to tumor necrosis factor (TNF), an inflammatory cytokine, blocking its action. Adalimumab is indicated for the treatment of Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, and juvenile idiopathic arthritis. It is not significantly immunogenic and only a small percentage of treated patients develop antibodies. However, in these patients, antibodies may be associated with lower trough levels of the drug. Results >12 AU/mL indicate the presence of anti-drug antibody.

Laboratory assay overview

Adalimumab is a therapeutic monoclonal antibody with the ability to bind to tumor necrosis factor (TNF), an inflammatory cytokine, blocking its action. Adalimumab is indicated for the treatment of Crohn?s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, and juvenile idiopathic arthritis. It is not significantly immunogenic and only a small percentage of treated patients develop antibodies. However, in these patients, antibodies may be associated with lower trough levels of the drug. Results >12 AU/mL indicate the presence of anti-drug antibody.

Quest Diagnostics population reference ranges

Quest Diagnostics calculates these statistical intervals for this specific assay and demographic group, not as universal optimal targets.